Group Leusen
Group Leusen
Group Leusen
About uitklapper, klik om te openen
For the past 20 years the Leusen group has investigated antibodies and Fc receptors, with a focus on IgA as a novel strategy for cancer immunotherapy. Fundamental research on the mode-of action of antibodies is combined with pre-clinical research for therapeutic applications. Next to this, targeting complement and its therapeutic application is another line of research within the Leusen lab.
Group members uitklapper, klik om te openen
Group leader
dr. J.H.W. Leusen Associate Professor
Postdocs
Geert van Tetering
Kevin Budding
Research technicians
Marco Jansen (senior)
Maaike Nederend
Petra Moerer
Kim Dijkxhoorn
Lauri Bloemenkamp (neurology)
Elisabeth de Zeeuw
PhD students
Mitchell Evers
Marjolein Stip
Arthur van Stigt (paediatrics)
Chilam Chan
Student assistant
Frederique van den Haak
Students
Corine Pleijte (honours student MED)
JiaLi Zheng (master)
Kunal Reshamwala (master)
Key publications uitklapper, klik om te openen
- Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, Matlung HL, Fauster A, Gomez-Eerland R, Bakker NAM, van der Schot S, Marijt KA, Verdoes M, Haanen JBAG, van den Berg JH, Neefjes J, van den Berg TK, Brummelkamp TR, Leusen JHW*, Scheeren FA*, Schumacher TN*. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat Med. 2019 Apr;25(4):612-619. doi: 10.1038/s41591-019-0356-z. Epub 2019 Mar 4. PMID: 30833751 View
- Brandsma AM, Schwartz SL, Wester MJ, Valley CC, Blezer GLA, Vidarsson G, Lidke KA, Ten Broeke T, Lidke DS, Leusen JHW. Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI. Sci Signal. 2018 Jul 24;11(540). pii: eaaq0891. doi: 10.1126/scisignal.aaq0891. PMID: 30042128 View
- Lohse S, Meyer S, Meulenbroek LA, Jansen JH, Nederend M, Kretschmer A, Klausz K, Möginger U, Derer S, Rösner T, Kellner C, Schewe D, Sondermann P, Tiwari S, Kolarich D, Peipp M, Leusen JH, Valerius T. An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo. Cancer Res. 2016 Jan 15;76(2):403-17. doi: 10.1158/0008-5472.CAN-15-1232. Epub 2015 Dec 3. View
- Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing. Cancer Immunol Res. 2015 Dec;3(12):1316-24. doi: 10.1158/2326-6066.CIR-15-0099-T. Epub 2015 Sep 25. View
- P. Boross, S. Lohse, M. Nederend, J.H.M. Jansen, G. van Tetering, M. Dechant, M. Peipp, L. Royle, L.P. Liew, L. Boon, N. van Rooijen, W.K. Bleeker, P.W. Parren, J.G.J. van de Winkel, T. Valerius, J.H.W. Leusen. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013 8:1213-1226. View
Fc receptors regulatory mechanisms and function in antibody therapy
Arianne Brandsma
2018
Antibody-mediated immunity against viral respiratory infections
Shamir Jacobino
2016
Intriguing good Alternative antibody therapy for solid and hematological cancers
Saskia Meyer
2016
Functional characterization of the high affinity IgG Receptor : making heads and tails of FcγRI
Cees van der Poel
2011
Collaborations uitklapper, klik om te openen
Academia
- Thomas Valerius, University of Kiel, Germany
- Friederike Meyer-Wentrup, lymphoma and neuroblastoma
- Meyaard group, tumor models
- Kuball group, antibodies
- Bont group, RSV and human milk
- Peperzak group
- Ton Schumacher, NKI CD47 block
- Timo van den Berg/ Hanke Matlung, Sanquin,SIRPa
- ...
Industry
- TigaTx
- Argenx
- Synthon
- Nutricia
- Modiquest
- Genmab
- ...
In the media uitklapper, klik om te openen
Onderzoeker van de week bij KWF
24 Jul 2017: Villa Joep financiert nieuw onderzoek
Education & Courses uitklapper, klik om te openen
11-12-13-14 November 2019 - Translational Immuno-oncology for PhD candidates: cancer & immune therapies from bench to bedside
Organizers: Yvonne Vercoulen and Jeanette Leusen
With this course we will bring a unique platform for students from 3 different PhD programs: Clinical & Translational Oncology, Infection and Immunity, Cancer Stem Cells & Development, to meet and learn from each other’s expertise.
The course will focus on Immuno-oncology, both on tumor effects on the immune system, and immune therapies. Both existing therapies, and novel therapies still under development or in trials will be discussed.
Students will be taught on the subject by medical specialists and scientists and will be challenged to work with their colleagues from another expertise to find solutions for a clinical or experimental problem.
Research programs uitklapper, klik om te openen
Infection and Immunity
Cancer
Child Health
Research interests uitklapper, klik om te openen
Next generation therapeutic antibodies
Fc receptors
Innate effector cells
IgA
Cancer
Complement targeting
Lung viruses
Contact uitklapper, klik om te openen
Jeanette Leusen
Phone +31 88 75 542 68
Location
Center for Translational Immunology
University Medical Center Utrecht
Heidelberglaan 100, 3584 CX Utrecht. Room H02.315